|August 5, 2014|
|07:43 EDT||AEZS||Aeterna Zentaris signs co-promotion services agreement with ASCEND Therapeutics|
Aeterna Zentaris announced a strategic co-promotion services agreement with ASCEND Therapeutics US. Under the terms of the agreement, expected to start in the Q4, Aeterna Zentaris will use its newly established commercial structure to market, in specific U.S. territories, ASCEND's EstroGel a non-patch transdermal, FDA approved and commercialized estrogen replacement therapy. For its part, ASCEND would market, in specific U.S. territories, MacrilenTM, Aeterna Zentaris' product for use in the evaluation of adult growth-hormone deficiency for which a New Drug Application is currently under review by the FDA, with a Prescription Drug User Fee Act date of November 5. In consideration for these co-promotion services, each party will be entitled to receive, from the other party, commissions on net sales of each other's product.
News For AEZS From The Last 14 Days
|November 25, 2015|
|13:11 EDT||AEZS||Aeterna Zentaris CEO responds to recent developments, says fundamentals 'strong'|
Aeterna Zentaris chairman and CEO David Dodd released a statement seeking to provide clarity on what he called recent "corporate developments." Dodd said, "Yesterday's announcement regarding corporate developments, which was required by IIROC on behalf of the Toronto Stock Exchange, caused some to question the fundamentals of our business. I want to reiterate that we believe the fundamentals remain strong. We have two products in Phase 3. One of the products, Zoptrex, is in the late stage of Phase 3. We instituted a confirmatory Phase 3 clinical trial of Macrilen after a panel of U.S. and EU endocrinology experts advised us to continue to seek approval for the compound because of their confidence in its efficacy and because there currently is no FDA-approved diagnostic test for adult growth hormone deficiency. That Phase 3 study recently enrolled its first patient, keeping us on track to conclude it by the end of 2016... We continue discussions with others about adding to our portfolio of promoted products and about the commercial rights to and development of Zoptrex in markets outside the United States."
|November 24, 2015|
|12:59 EDT||AEZS||GEO Investing says Aeterna Zentaris rally 'totally unwarranted'|
GEO Investing tweeted, "We believe $AEZS pump is totally unwarranted and that stock will quickly follow if $KBIO sells off."
|11:30 EDT||AEZS||Aeterna Zentaris says no corporate developments to account for stock movement|
Aeterna Zentaris, at the request of IIROC on behalf of the Toronto Stock Exchange, confirms that as of the date of this news release there are no corporate developments that would cause the recent movements in the company's share price.
|November 19, 2015|
|08:32 EDT||AEZS||Aeterna Zentaris enrolls first patient for Phase 3 trial of Macrilen|
Aeterna Zentaris has enrolled the first patient for its confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen, a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency. Based on meetings with the FDA as well as the EMA and subsequent written scientific advice, the company believes that the study meets the FDA's and the EMA's study-design expectations allowing US and European approval, if successful.
|November 18, 2015|
|08:34 EDT||AEZS||Aeterna Zentaris announces share consolidation details for NASDAQ compliance|
Subscribe for More Information
|November 16, 2015|
|11:52 EDT||AEZS||Aeterna Zentaris announces shareholder approval of 100-for-1 share consolidation|
Aeterna Zentaris announced that the holders of its issued and outstanding common shares approved a share consolidation and that the company has determined that the consolidation ratio will be 100-for-1. The company intends to implement the consolidation in the coming days and will shortly provide all relevant details regarding the consolidation, including its effective date and the date on which the common shares are expected to commence trading on a post-consolidation basis on the NASDAQ Capital Market and the Toronto Stock Exchange and information for registered and beneficial shareholders to exchange their pre-consolidation for post-consolidation common shares. The company also announces that Marcel Aubut is no longer a member of the Board of Directors effective November 16.
|November 13, 2015|
|10:17 EDT||AEZS||Aeterna Zentaris to host special shareholder meeting|
Special shareholder meeting to be held on November 16 at 9:30 am.